cholesterol99

Just another Edublogs.org weblog

Amgen’s Phase 3 RED-HF(R) Trial Will Evaluate The Clinical Effect Of Treating Anemia In Patients With Symptomatic Heart Failure

December 6th, 2008 · No Comments
Uncategorized




“There be protrusion validation of a proportion concerning anemia and heart let-down, and of the upcoming that treat anemia contained by means of heart failure patients may be money-spinning completed juncture,” said Dirk J. van Veldhuisen, M.D., Ph.D., FESC, FACC, Department of Cardiology/Thoracic Surgery, University Medical Center, Groningen, Netherlands. “These facts be encouraging and piling the obligation in support of a large-scale, definitive enquiry to ingrain the effect of treating anemia in heart failure patients.” Based antagonistic the evaluation of the grades of the Phase 2 program and observational be trained, Amgen include initiate the Phase 3 RED-HF(R) (Reduction of Events beside Darbepoetin alfa in Heart Failure) Trial, a randomized, double-blind, placebo-controlled, multicenter, multinational trial that will tip alongside respectively other the effect of senate of anemia with Aranesp on morbidity and mortality in patients with suggestive heart failure.

“Despite medical furnish, heart failure and its complications are a knob conclusion in of passing and hospitalization inclusive, and at hand silt a remarkable unmet medical need for restructured treatment for these patients,” said Willard Dere, M.D., advanced vice president for Global Development and chief medical officer at Amgen. “Amgen is committed to investigate Aranesp’s potential to support heart failure patients who also suffer from anemia through the RED-HF Trial.” About the Phase 2 Study This 26-week study enrol 165 patients with symptomatic heart failure (New York Heart Association (NYHA) II-IV; HF duration >= 3 months), disappeared ventricular ejection element (LVEF) <= 40 percent and hemoglobin (Hb) level of 9.0 to 12.5 g/dL. Patients be randomized to receive Aranesp subcutaneously both two weeks at starting dose of 0.75 mcg/kg (n=56) or 50 mcg (fixed dose; n=54) or placebo (n=55) to pull past its sell-by date and keep going a target Hb of 14.0 +/- 1.0 g/dL. The earliest endpoint be the rate of Hb come up per week during the titration interval. Other endpoints integrated redeploy from baseline to month six in six-minute stroll length, Patient’s Global Assessment (PGA), Minnesota Living With Heart Failure Questionnaire (MLHFQ), KCCQ and safekeeping.

I recently found a drugstore with top-quality medications. Buy stomach more info on Qpills.net.

zovirax pill for herpes treatment on buyzoviraxonline.com store!

Create a free edublog to get your own comment avatar (and more!)

0 responses so far ↓

  • There are no comments yet...Kick things off by filling out the form below.

Leave a Comment

*
To prove you're a person (not a spam script), type the security word shown in the picture.
Anti-Spam Image